Results for 'durvalumab'
New Realities of Phase I Clinical Trials in the Era of
Oct 6th • 5 mins read
The correlation between the costs and clinical benefits of PD-1/PD-L1 inhibitors in malignant tumors: An evaluation based on ASCO and ESMO frameworks
Feb 22nd • 9 mins read
Estimated Medicare Spending on Cancer Drug Indications With a Confirmed Lack of Clinical Benefit After US Food and Drug Administration Accelerated
Oct 17th • 5 mins read